CONTEMPORARY MANAGEMENT OF VENOUS THROMBOEMBOLISM: CLINICAL RISK STRATIFICATION, THROMBOPROPHYLAXIS, AND ANTICOAGULATION WITH ORAL ANTICOAGULANTS
DOI:
https://doi.org/10.36557/2674-9432.2026v5n2p867-877Palavras-chave:
Venous thromboembolism; Risk stratification; Thromboprophylaxis; Direct oral anticoagulants; Personalized medicine.Resumo
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains a major global health concern due to its high morbidity and mortality. Over the past decades, significant advances in the understanding of its pathophysiology and management have led to a shift from standardized therapeutic approaches to more individualized strategies. This narrative review aims to analyze contemporary VTE management, focusing on clinical risk stratification, thromboprophylaxis, and the use of direct oral anticoagulants (DOACs). A narrative literature review was conducted using PubMed/MEDLINE, Scopus, Web of Science, and ScienceDirect, including studies published between 2015 and 2026. Clinical trials, systematic reviews, and international guidelines were analyzed to synthesize current evidence. Findings highlight the central role of risk stratification tools, such as the Pulmonary Embolism Severity Index (PESI), in guiding clinical decisions, including outpatient management for low-risk patients. Thromboprophylaxis strategies have evolved with the implementation of validated risk assessment models, particularly in hospitalized populations. The introduction of DOACs represents a major advancement, offering comparable or superior efficacy to vitamin K antagonists, with improved safety profiles and greater convenience. However, their use requires careful consideration in specific populations, including patients with renal impairment, cancer, or pregnancy. Overall, contemporary VTE management reflects a paradigm shift toward personalized medicine, integrating clinical assessment, evidence-based protocols, and patient-centered decision-making. Despite these advances, challenges remain in guideline implementation and treatment individualization. Future research should focus on optimizing long-term outcomes and refining risk stratification models to further enhance clinical care.
Downloads
Referências
AGNELLI, G. et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine, Boston, v. 369, n. 9, p. 799-808, 2013. DOI: 10.1056/NEJMoa1302507. Disponível em: https://pubmed.ncbi.nlm.nih.gov/23808982/. Acesso em: 11 Mar. 2026.
BARBAR, S. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. Journal of Thrombosis and Haemostasis, Oxford, v. 8, n. 11, p. 2450-2457, 2010. DOI: 10.1111/j.1538-7836.2010.04044.x. Disponível em: https://pubmed.ncbi.nlm.nih.gov/20738765/. Acesso em: 11 Mar. 2026.
BAUERSACHS, R. et al. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine, Boston, v. 363, n. 26, p. 2499-2510, 2010. DOI: 10.1056/NEJMoa1007903. Disponível em: https://pubmed.ncbi.nlm.nih.gov/21128814/. Acesso em: 09 Mar. 2026.
BÜLLER, H. R. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine, Boston, v. 366, n. 14, p. 1287-1297, 2012. DOI: 10.1056/NEJMoa1113572. Disponível em: https://pubmed.ncbi.nlm.nih.gov/22449293/. Acesso em: 07 Mar. 2026.
HOKUSAI-VTE INVESTIGATORS. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine, Boston, v. 369, n. 15, p. 1406-1415, 2013. DOI: 10.1056/NEJMoa1306638. Disponível em: https://pubmed.ncbi.nlm.nih.gov/23991658/. Acesso em: 09 Mar. 2026.
JIMÉNEZ, D. et al. Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism. Archives of Internal Medicine, Chicago, v. 170, n. 15, p. 1383-1389, 2010. DOI: 10.1001/archinternmed.2010.199. Disponível em: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/775646. Acesso em: 06 Mar. 2026.
KONSTANTINIDES, S. V. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, Oxford, v. 41, n. 4, p. 543-603, 2020. DOI: 10.1093/eurheartj/ehz405. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31504429/. Acesso em: 11 Mar. 2026.
LEIDI, A. et al. Risk stratification in patients with acute pulmonary embolism. Seminars in Thrombosis and Hemostasis, New York, v. 48, n. 6, p. 705-715, 2022. DOI: 10.1055/s-0042-1744230. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35566658/. Acesso em: 10 Mar. 2026.
LUTSEY, P. L.; BECKMAN, J. A. Epidemiology and prevention of venous thromboembolism. Nature Reviews Cardiology, London, v. 20, n. 4, p. 248-262, 2023. DOI: 10.1038/s41569-022-00769-4. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36258120/. Acesso em: 10 Mar. 2026.
ORTEL, T. L. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Advances, Washington, v. 4, n. 19, p. 4693-4738, 2020. DOI: 10.1182/bloodadvances.2020001830. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33007077/. Acesso em: 05 Mar. 2026.
SCHULMAN, S. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine, Boston, v. 361, n. 24, p. 2342-2352, 2009. DOI: 10.1056/NEJMoa0906598. Disponível em: https://pubmed.ncbi.nlm.nih.gov/19966341/. Acesso em: 07 Mar. 2026.
STEVENS, S. M. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest, Chicago, v. 160, n. 6, p. e545-e608, 2021. DOI: 10.1016/j.chest.2021.07.055. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34352278/. Acesso em: 09 Mar. 2026.
THOMAS, S. E. et al. Diagnosis of pulmonary embolism: a review of evidence-based approaches. Cureus, Palo Alto, v. 16, n. 6, e62557, 2024. DOI: 10.7759/cureus.62557. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11242034/. Acesso em: 11 Mar. 2026.
TSIAMITA, O. et al. Post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension: diagnosis and management. British Journal of Hospital Medicine, London, v. 84, n. 9, p. 1-10, 2023. DOI: 10.12968/hmed.2023.0114. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37646549/. Acesso em: 09 Mar. 2026.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Mirella Cristina Mazuqueli Marques, Lucileia Mazuqueli Marques, Rodolfo de Oliveira Medeiros, Dianah Dantas Pulvirenti, Fabiana Campos Castro de Carvalho, Arthur Menegucci Vicenconi, Ana Carolina Fontana Bolsoni, José Gabriel Cavalcanti Garcia, Maria Júlia Daniel Peixoto, Edna Pereira da Silva, João Pedro Zanatto, Bruna Gonçalves Manzoni
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Você tem o direito de:
- Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
- Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
- O licenciante não pode revogar estes direitos desde que você respeite os termos da licença.
De acordo com os termos seguintes:
- Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
- Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
